287 430

Cited 6 times in

Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

Authors
 Jie-hyun Kim  ;  Kwang-hyub Han  ;  Kwan Sik Lee  ;  Young Nyun Park  ;  Sang Hoon Ahn  ;  Chae Yoon Chon  ;  Young Myoung Moon 
Citation
 YONSEI MEDICAL JOURNAL, Vol.47(6) : 793-798, 2006 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2006
MeSH
Adult ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use* ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Hepatitis C, Chronic/drug therapy* ; Hepatitis C, Chronic/immunology ; Hepatitis C, Chronic/virology ; Humans ; Interferon-alpha/adverse effects ; Interferon-alpha/therapeutic use* ; Korea ; Male ; Middle Aged ; Retrospective Studies ; Ribavirin/adverse effects ; Ribavirin/therapeutic use*
Keywords
Chronic hepatitis C ; interferons ; ribavirin ; long-term effects
Abstract
Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3%. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection.
Files in This Item:
T200603746.pdf Download
DOI
10.3349/ymj.2006.47.6.793
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jie-Hyun(김지현) ORCID logo https://orcid.org/0000-0002-9198-3326
Park, Young Nyun(박영년) ORCID logo https://orcid.org/0000-0003-0357-7967
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Chon, Chae Yoon(전재윤)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/110854
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links